-
Mashup Score: 2
Data from the prospective genomic profiling
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Sorafenib maintenance post-transplantation can reduce relapse and is well tolerated in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation. This strategy could be a suitable therapeutic option for patients with FLT3-ITD acute myeloid leukaemia.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Also in our Sept issue: #Sorafenib maintenance in patients with FLT3-ITD #acutemyeloidleukaemia undergoing allogeneic haematopoietic #stemcelltransplantation: an open-label, multicentre, randomised phase 3 trial https://t.co/eoNPkeOCGC
-
-
Mashup Score: 1
Sorafenib maintenance post-transplantation can reduce relapse and is well tolerated in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation. This strategy could be a suitable therapeutic option for patients with FLT3-ITD acute myeloid leukaemia.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New research: #Sorafenib maintenance in patients with FLT3-ITD #acutemyeloidleukaemia undergoing allogeneic haematopoietic #stemcelltransplantation: an open-label, multicentre, randomised phase 3 trial https://t.co/eoNPkeOCGC
-
-
Mashup Score: 0
The safety and activity of venetoclax plus chemotherapy in paediatric patients with heavily relapsed and refractory acute myeloid leukaemia suggests that this combination should be tested in newly diagnosed paediatric patients with high-risk acute myeloid leukaemia.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Also in the April issue: phase 1 study of #venetoclax in combination with #cytarabine with or without #idarubicin in #children with relapsed or refractory #acutemyeloidleukaemia #leusm https://t.co/OsWP5CNEo7
-
-
Mashup Score: 0Decreased vitamin C uptake mediated by SLC2A3 promotes leukaemia progression and impedes TET2 restoration - 4 year(s) ago
Vitamin C suppresses leukaemogenesis by modulating Tet methylcytosine dioxygenase (TET) activity. However, its beneficial effect in the treatment of patients with acute myeloid leukaemia (AML) remains controversial. In this study, we aimed to identify a potential predictive biomarker for vitamin C treatment in AML. Gene expression patterns and their relevance to the survival of AML patients were…
Source: British Journal of CancerCategories: Hem/OncsTweet-
#ICYMI Hong and colleages conducted a new study which aimed to identify a potential predictive biomarker for vitamin C treatment in #AcuteMyeloidLeukaemia https://t.co/7ttzqSywH4 @LIUJUN49994947
-
-
Mashup Score: 0
There is growing evidence that spleen tyrosine kinase (SYK) is critical for acute myeloid leukaemia (AML) transformation and maintenance of the leukemic clone in AML patients. It has also been found to be over-expressed in AML patients, with activating mutations in foetal liver tyrosine kinase 3 (FLT3), particularly those with internal tandem duplications (FLT3-ITD), where it transactivates…
Source: British Journal of CancerCategories: Hem/OncsTweet-
Griffin and team have concluded that, given the significant transforming role of spleen tyrosine kinase in other tumours, targeting USP10 may have broader applications in cancer. https://t.co/TXwrdfYtKz #AcuteMyeloidLeukaemia
-
Feasibility and preliminary efficacy results of the Beat #acutemyeloidleukaemia study: Data from prospective genomic profiling 👉https://t.co/M8Mb81tgXd #PrecisionMedicine #leukaemia #leusm https://t.co/JeWnC2FGXD